Abstract. Naringenin, one of the most abundant flavonoids in citrus fruits and grapefruits, has been reported to exhibit anti-inflammatory and antitumor activities. However, the cellular and molecular mechanisms underlying the naringenin anti-inflammatory activity are poorly understood. In this study, we conducted an investigation of the inhibitory effects of naringenin on the production of lipopolysaccharide (LPS)-induced pro-inflammatory mediators in BV2 microglial cells. We found that pre-treatment with naringenin prior to treatment with LPS significantly inhibited excessive production of nitric oxide (NO) and prostaglandin E 2 (PGE 2 ) in a dose-dependent manner. The inhibition was associated with downregulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression. Naringenin also attenuated the production of pro-inflammatory cytokines and chemokines, including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCP-1) by suppressing expression of mRNAs for these proteins. In addition, the molecular mechanism underlying naringenin-mediated attenuation in BV2 cells has a close relationship to suppressing translocation of the nuclear factor-κB (NF-κB) p65 subunit into the nucleus and the phosphorylation of Akt and mitogen-activated protein kinases (MAPKs). These findings suggest that naringenin may provide neuroprotection through suppression of pro-inflammatory pathways in activated BV2 microglial cells.
Introduction
Microglia are glial cells that enter the brain early in embryogenesis and develop in parallel with the maturation of the nervous system. Under normal conditions, these microglia play a major role in host defense and tissue repair in the central nervous system (CNS) (1) (2) (3) . However, in response to injury, infection or inflammation, microglia readily become activated and secrete neurotoxic and pro-inflammatory mediators, including nitric oxide (NO), prostaglandin E 2 (PGE 2 ), reactive oxygen species (ROS) and pro-inflammatory cytokines such as interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-α (TNF-α) (4) (5) (6) . Therefore, microglial activation appears to play a pivotal role in the initiation and progression of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), cerebral ischemia, multiple sclerosis and trauma (7) (8) (9) . Thus, regulating microglial activation and downregulation of pro-inflammatory mediators in microglia may have the therapeutic potential to reduce neuronal injury or death in neurodegenerative diseases.
Flavonoids are a diverse group of plant natural products synthesized from phenylpropanoid and acetate-derived precursors. They are becoming an important source of novel agents with pharmaceutical potential and have attracted a great deal of attention in recent years for their role in the prevention of chronic diseases (9) (10) (11) (12) (13) . Among them, naringenin and its glycoside naringin are abundant in grapefruit and citrus fruits and juices (14, 15) . Previous studies have shown that naringenin inhibits CYP3A4 activity and exhibits aorta dilatory, antioxidant, antiestrogenic, antiproliferative and antimetastatic effects (16) (17) (18) (19) (20) . Recently, naringenin, but not naringin, has been reported to induce apoptosis in various human cancer cells and treatment with a similar dose showed no toxic effect on normal cells (21) (22) (23) (24) (25) . Although numerous studies on the antioxidant and anticancer effects of naringenin have been reported, the cellular and molecular mechanisms underlying naringenin-induced anti-inflammatory effects are not clear.
In this study, we investigated the inhibitory effects of naringenin and the way in which it induces anti-inflammatory mechanisms in lipopolysaccharide (LPS)-stimulated inflammatory mediator production in murine BV2 microglia. As a result of our findings, we suggest that naringenin may be a candidate for use in treatment of various neurodegenerative disorders in the brain.
Materials and methods
Cell culture. BV2 murine microglial cells were obtained from Professor I.W. Choi (Inje University, Busan, Republic of Korea). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin and were maintained in a humidified incubator with 5% CO 2 . Naringenin (SigmaAldrich, St. Louis, MO) was dissolved in dimethyl sulfoxide (DMSO) and dilutions were made in DMEM. The final concentration of DMSO in the medium was <0.05% (vol/vol) which showed no influence on cell growth. In all experiments, cells were pre-treated with the indicated concentrations of naringenin for 1 h before addition of LPS (Escherichia coli 026:B6; Sigma-Aldrich).
Cell viability assay. Cell viability was measured based on formation of blue formazan metabolized from colorless 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) by mitochondrial dehydrogenases, which are active only in live cells. BV2 cells were plated into 24-well plates at a density of 2x10 5 cells/well for 24 h and then washed. The cells incubated with various concentrations of naringenin were treated with or without 0.5 µg/ml LPS for 24 h and then incubated in 0.5 mg/ml MTT solution. Three hours later, the supernatant was removed and formation of formazan was measured at 540 nm using a microplate reader (26) .
Measurement of NO production. The concentrations of NO in culture supernatants were determined as nitrite, a major stable product of NO, using the Griess reagent (Sigma-Aldrich). After cells (5x10 5 cells/ml) were stimulated in 24-well plates for 24 h, 100 µl of each cultured medium was mixed with the same volume of the Griess reagent [1% sulfanilamide/0.1% N-(1-naphthyl)-ethylenediamine dihydrochloride/2.5% H 3 PO 4 ]. Nitrite levels were determined using an ELISA plate reader at 540 nm and nitrite concentrations were calculated by reference to a standard curve generated by known concentrations of sodium nitrite (27) . 2 production. BV2 cells were incubated with naringenin in either the presence or absence of LPS (0.5 µg/ml) for 24 h. Following the manufacturer's instructions, a volume of 100 µl of culture-medium supernatant was collected for determination of PGE 2 concentration by ELISA (Cayman Chemical, Ann Arbor, MI).
Measurement of PGE
Reverse transcriptase-polymerase chain reaction. Total-RNA was isolated using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA). Total-RNA (1.0 µg) obtained from cells was primed with random hexamers to synthesize complementary DNA using M-MLV reverse transcriptase (Promega, Madison, WI) according to the manufacturer's instructions. Polymerase chain reaction (PCR) was performed for amplification of the inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), IL-1β, TNF-α and monocyte chemoattractant protein-1 (MCP-1) genes from the cDNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. Conditions for the PCR reactions were 1x (94˚C for 3 min); 35x (94˚C for 45 sec, 58˚C for 45 sec, and 72˚C for 1 min); and 1x (72˚C for 10 min). Amplification products obtained by PCR were electrophoretically separated on 1% agarose gel and visualized by EtBr staining.
Protein extraction and western blot analysis. For western blot analysis, cells were harvested and washed twice in PBS at 4˚C. Total cells lysates were lysed in lysis buffer [40 mM Tris (pH 8.0), 120 mM, NaCl, 0.5% NP-40, 0.1 mM sodium orthovanadate, 2 µg/ml aprotinin, 2 µg/ml leupeptin and 100 µg/ml phenymethylsulfonyl fluoride]. The supernatants were collected and protein concentrations were then measured with protein assay reagents (Pierce Biotechnology, Inc., Rockford, IL). Equal amounts of protein extracts were denatured by boiling at 95˚C for 5 min in sample buffer (0.5 M Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 0.1% bromophenol blue, 10% β-mercaptoethanol) in a ratio of 1:1, subjected to 8-10% sodium dodecyl sulfate (SDS)-polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Schleicher and Schuell Bioscience, Inc., Keene, NH) by electroblotting. The membranes were blocked with 5% non-fat dry milk in PBS with Tween-20 buffer (PBS-T) (20 mM Tris, 100 mM NaCl, pH 7.5 and 0.1% Tween-20) for 1 h at room temperature. Membranes were then incubated overnight at 4˚C with the primary antibodies, probed with enzyme-linked secondary antibodies and visualized using an enhanced chemiluminescence (ECL) kit (Amersham Life Science, Arlington Heights, IL) according to the manufacturer's instructions. In a parallel experiment, nuclear proteins were prepared using the NE-PER nuclear extraction reagent (Pierce Biotechnology, Inc.) according to the manufacturer's protocol.
Enzyme immunosolvent assay (ELISA).
The levels of IL-1β, TNF-α (R&D Systems, Minneapolis, MN) and MCP-1 (BioLegend, San Diego, CA) were measured by the ELISA kits according to the manufacturer's instructions. Briefly, BV2 cells (5x10 5 cells/ml) were plated in 24-well plates and pre-treated with the indicated concentrations of naringenin for 1 h before treatment of 0.5 µg/ml LPS for 24 h. One hundred microliters of culture-medium supernatants were collected for determination of IL-1β, TNF-α and MCP-1 concentration by ELISA (28) .
Electrophoretic mobility shift assay (EMSA)
. DNA-protein binding assays were carried out with nuclear extract. Synthetic complementary nuclear factor-κB (NF-κB; 5'-AGTTGAGGGG ACTTTCCCAGGC-3') binding oligonucleotides (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were 3'-biotinylated using the biotin 3'-end DNA labeling kit (Pierce Biotechnology, Inc.) according to the manufacturer's instructions and annealed for 30 min at room temperature. The reaction mixture was electrophoretically separated on a 4% polyacrylamide gel in 0.5X Tris-borate buffer and transferred to a nylon membrane. The transferred DNAs were cross-linked to the membrane at 120 mJ/cm 2 . Horseradish peroxidase-conjugated streptavidin was used according to the manufacturer's instructions to detect the transferred DNA.
NF-κB luciferase assay. A total of 1x10
6 BV2 cells were transfected with 2 µg NF-κB-luciferase reporter plasmids (BD Biosciences, San Jose, CA) using lipofectamine according to the manufacturer's protocol (Gibco-BRL). After incubating with DNA-lipofectamine mixtures, the cells were pre-incubated in the presence or absence of naringenin before being stimulated with LPS for 6 h. Cells were then washed twice with PBS and lysed with reporter lysis buffer (Promega). After vortexing and centrifugation at 12,000 x g for 1 min at 4˚C, the supernatant was stored at -70˚C for the luciferase assay. After 20 µl of the cell extract was mixed with 100 µl of the luciferase assay reagent at room temperature, the mixture was measured a microplate luminometer LB96V (Perkin-Elmer, Foster City, CA) (29) .
Statistical analysis. Data values represent the means ± SD. Statistical significance was determined using analysis of variance, followed by Student's t-test. A value of P<0.05 was accepted as statistically significant.
Results
Naringenin attenuates NO and PGE 2 production in LPS-stimulated BV2 microglia. To determine levels of NO production, we measured nitrite released into the culture medium using the Griess reagent. For this study, BV2 cells were pre-treated with various concentrations of naringenin for 1 h prior to stimulation with LPS. According to the NO detection assay, treatment with LPS alone resulted in higher NO production by cells as compared with that generated by the control. However, pre-treatment with naringenin significantly repressed the levels of NO production in LPS-stimulated BV2 cells in a concentration-dependent manner (Fig. 1A) . PGE 2 is another important inflammatory mediator. We evaluated the effects of naringenin on PGE 2 production in LPS-stimulated BV2 cells. As indicated in Fig. 1B , treatment of BV2 cells with LPS alone resulted in a marked increase in PGE 2 release in comparison to untreated controls. However, naringenin inhibited LPS-induced PGE 2 production in a concentrationdependent manner. These results suggest that pre-treatment with naringenin suppresses LPS-mediated expression of proinflammatory mediators. In order to exclude cytotoxic effects of naringenin in BV2 microglia, we evaluated the viability of BV2 cells incubated with or without 0.5 µg/ml LPS in the absence or presence of naringenin using MTT assays. Concentrations (40-80 µM) used for inhibition of NO and PGE 2 production did not affect cell viability (data not shown), confirming that inhibition of NO and PGE 2 production in LPS-stimulated BV2 cells was not due to a cytotoxic action of naringenin.
Naringenin decreases expression of LPS-stimulated iNOS and COX-2 mRNA and protein.
We carried out RT-PCR and western blot analyses to determine whether inhibition of NO and PGE 2 production were associated with decreased levels of iNOS and COX-2 expression. As shown in Fig. 2 , iNOS and COX-2 mRNA levels were detectable 6 h after LPS treatment, whereas the protein levels of these enzymes were detected in whole cell lysates 24 h after LPS treatment. However, naringenin markedly decreased both mRNA and protein levels for iNOS and COX-2. The results suggest that naringenin-induced reductions in the expression of iNOS and COX-2 were the cause of the inhibition of NO and PGE 2 production. Cell lysates were then prepared and western blot analysis was performed using antibodies specific for murine iNOS and COX-2. (B) After LPS treatment for 6 h, total-RNA was prepared for RT-PCR analysis of iNOS and COX-2 gene expression in LPSstimulated BV2 microglia. ERK and GAPDH were used as internal controls for western blot analysis and RT-PCR assays, respectively. The experiment was repeated 3 times and similar results were obtained.
Naringenin suppresses induction of inflammatory cytokines in LPS-stimulated BV2 microglia.
We next determined whether or not naringenin suppresses production of pro-inflammatory cytokines such as IL-1β and TNF-α. For this study, BV2 cells were incubated with naringenin in the absence or presence of LPS for 24 h and cytokine levels were evaluated in the culture supernatants. As shown in Fig. 3A and B, the levels of IL-1β and TNF-α were markedly increased in the culture media of LPS-stimulated BV2 microglia. However, pre-treatment with naringenin resulted in a significant decrease in the release of these pro-inflammatory cytokines in a concentration-dependent manner. In a parallel experiment using RT-PCR, we studied the effects of naringenin on LPS-induced IL-1β and TNF-α mRNA expression. As shown in Fig. 3B , IL-1β and TNF-α mRNA transcription also decreased following naringenin treatment. These results suggest that naringenin suppresses pro-inflammatory cytokine production through alteration of the transcription levels of IL-1β and TNF-α in activated microglia.
Naringenin attenuates MCP-1 protein and mRNA in LPS-stimulated BV2 microglia.
We determined the effects of naringenin on production of chemokine MCP-1. As shown in Fig. 4A , naringenin alone had no effect on the production of MCP-1 in BV2 cells, but the levels of MCP-1 were markedly increased in the culture media of LPS-stimulated BV2 microglia. However, pre-treatment with naringenin resulted in a concentration-dependent decrease of MCP-1 production, which was associated with a reduction in LPS-mediated increases in MCP-1 mRNA levels. These results also indicate that naringenin regulates production of MCP-1 at the transcriptional level.
Naringenin blocks NF-κB in LPS-stimulated BV2 microglia.
Because activation of NF-κB is the key event for the induction of all major pro-inflammatory mediators, we next investigated whether naringenin modulates the activation of NF-κB in BV2 microglia in response to LPS. As shown in p65 subunit from the cytosol to the nucleus. LPS-induced IκB degradation was inhibited after 30 min of exposure to naringenin. Also, naringenin inhibited nuclear translocation of the NF-κB p65 protein. According to the EMSA assay, LPS treatment caused a significant increase in the DNA-binding activity of NF-κB (Fig. 6A) . In contrast, treatment with naringenin significantly suppressed the LPS-induced DNA binding activity of NF-κB. We next tried to confirm inhibition of LPS-induced NF-κB activation by naringenin by luciferase assay. For this study, BV2 cells transfected with NF-κB-luciferase reporter plasmids were pre-treated with naringenin for 1 h and stimulated with LPS for 6 h and then luciferase activity was measured. As shown in Fig. 5B , LPS significantly enhanced NF-κB activity up to 8-fold over the basal level, while naringenin significantly inhibited LPS-induced NF-κB activity. Taken together, the above findings demonstrate involvement of the NF-κB pathway in the anti-inflammatory effect of naringenin in LPS-stimulated BV2 cells.
Naringenin reduces LPS-induced phosphorylation of Akt and MAPKs in LPS-stimulated BV2 microglia.
To investigate other intracellular mechanisms responsible for the inhibitory effect of naringenin on inflammatory mediators, we examined the effect of naringenin on Akt and mitogen-activated protein kinases (MAPKs) signaling pathways. As shown in Fig. 7 , phosphorylation of Akt was increased within 15 min after LPS stimulation and naringenin pre-treatment resulted in significant blockage of LPS-induced Akt phosphorylation. Furthermore, stimulation of BV2 cells with LPS led to rapid activation of p38MAPK, ERK and JNK, with the peak levels of each phospho-MAPK occurring 15-60 min after addition of LPS. However, naringenin pre-treatment significantly inhibited phosphorylation of MAPKs in LPS-stimulated BV2 microglia (Fig. 7) . This finding suggests that naringenin is capable of disrupting key signal transduction pathways such as Akt and MAPKs that are activated by LPS in BV2 microglia; the disruption prevents production of pro-inflammatory mediators.
Discussion
In this study, we demonstrated that naringenin in activated BV2 microglial cells inhibits LPS-induced production of Figure 5 . Effects of naringenin on LPS-induced NF-κB translocation and IκB degradation in BV2 microglia. Cells were treated with naringenin for 1 h before LPS treatment (0.5 µg/ml) for the indicated times. Nuclear and cytosolic proteins were subjected to 10% SDS-polyacrylamide gels followed by western blot analysis using anti-NF-κB p65 and anti-IκB-α antibodies. Results are representative of those obtained from 3 independent experiments. ERK and lamin B were used as internal controls for nuclear and cytosolic fractions, respectively. Effects of naringenin on AKT and MAPKs activation induced by LPS in BV2 microglia. BV2 cells were treated with the indicated concentrations of naringenin for 1 h prior to LPS (0.5 µg/ml) treatment for the indicated times. Total protein was subjected to 10% SDS-polyacrylamide gels, followed by western blot analysis using the indicated antibodies. Proteins were visualized using an ECL detection system. pro-inflammatory mediators such as NO and PGE 2 , cytokines, including TNF-α and IL-1β, and the chemokine MCP-1. These effects were accompanied by downregulation of NF-κB activity and inactivation of Akt and MAPK signaling pathways. In theory, downregulators of these inflammatory molecules have been considered as candidate anti-inflammatory drugs to alleviate progression of neurodegenerative diseases caused by activation of microglia (30) (31) (32) . Therefore, the inhibition of pro-inflammatory molecules by naringenin shown in this study could play a beneficial role in the treatment of neurodegenerative diseases.
NO, PGE 2 and pro-inflammatory cytokines and chemokines, such as TNF-α, IL-6, IL-1β and MCP-1, have been implicated as important mediators in the process of inflammation. Several lines of evidence have shown that the activation of microglia induced by CNS injury or infection is associated with neurodegenerative disorders and the release of NO and PGE 2 , and with subsequent release of pro-inflammatory cytokines and chemokines (4) (5) (6) . Previously, many studies have shown that expression of COX-2 and iNOS, key enzymes for NO and PGE 2 , are upregulated in activated glial cells. Also, pro-inflammatory cytokines activate the transcription of COX-2 and iNOS genes, and anti-inflammatory drugs may also effectively reduce NO and PGE 2 production (1, (4) (5) (6) . In this study, we demonstrate that naringenin treatment significantly inhibits NO and PGE 2 production in LPS-stimulated BV2 microglia. The inhibitory effects of naringenin attenuated the expression iNOS and COX-2 mRNA and protein, indicating that the effect of naringenin occurs at the transcriptional level. The present data also indicate that naringenin inhibits the production of pro-inflammatory cytokines and chemokines such as TNF-α, IL-1β and MCP-1. Thus, the inhibitory actions of naringenin on the production of inflammatory mediators occurs at the transcriptional level.
The transcription factor NF-κB is a primary regulator of genes that are involved in production of pro-inflammatory cytokines and enzymes involved in the inflammatory process (33) (34) (35) . In addition, involvement of the phosphoinositide 3-kinase (PI3K)/Akt pathway in the expression of inflammatory mediators in microglia through activation of NF-κB has been shown (36, 37) . As a result of its key role in several pathologic conditions, NF-κB is a major drug target in a variety of diseases. The blockade of NF-κB transcriptional activity in microglial is also known to suppress expression of iNOS, COX-2, pro-inflammatory cytokines and chemokines including TNF-α, IL-1β and MCP-1 (38) (39) (40) . Therefore, many putative anti-inflammatory therapies seek to block NF-κB activity. We demonstrated that naringenin causes marked blockage of LPS-induced IκB-α degradation, and of NF-κB translocation and transcriptional activity. Our findings suggest that downregulation of pro-inflammatory mediators by naringenin is due to inhibition of the NF-κB pathway. Furthermore, naringenin significantly inhibited Akt activation in LPS-stimulated BV2 microglia, indicating that naringenin inhibits LPS-induced NF-κB activation via inactivation of the PI3K/AKT signaling pathway.
Involvement of various intracellular signaling pathways, such as MAPKs, in inflammatory mediator induction has been reported (41) (42) (43) (44) . LPS is also known to activate a series of MAPKs such as ERK, p38MAPK and JNK in microglial cells (45) . Therefore, experiments were performed to determine whether naringenin tightly regulates expression of MAPKs to induce anti-inflammatory effects in LPS-stimulated BV2 microglia. The present study indicates that naringenin is a potent inhibitor of MAPKs expression induced by LPS stimulation in BV2 microglia. Although, further studies are needed to validate roles for MAPKs in changes in various inflammatory mediators in microglia, the present results suggest that the anti-inflammatory effects of naringenin are associated with inhibition of the MAPKs signaling pathway.
In conclusion, the results presented in this study, demonstrate that naringenin inhibits LPS-induced NO and PGE 2 production by suppressing iNOS and COX-2 mRNA and protein expression in BV2 microglial cells. Naringenin also inhibits the production of pro-inflammatory cytokines and chemokines (TNF-α, IL-1β and MCP-1) by suppressing their transcriptional activity. The inhibitory action of naringenin was mediated by prevention of NF-κB activation and by inhibition of IκB-degradation, which is accompanied by the blocking of PI3K/Akt and MAPKs pathways. As a result of the findings presented in this study, we suggest that naringenin may provide an effective treatment for many inflammatory and neurodegenerative diseases.
